Cat. No. | Product name | CAS No. |
DC67021 | RG-7652 Featured | |
DC67022 |
Lodelcizumab
Featured
Lodelcizumab is a monoclonal antibody. Lodelcizumab can be used for the research of hypercholesterolemia. |
1355338-54-3 |
DC67023 | Amvuttra Featured | |
DC67024 |
Inotersen
Featured
Inotersen is an antisense oligonucleotide that inhibits hepatic production of transthyretin (TTR). The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Inotersen sodium) that retains the same biological activity. |
1492984-65-2 |
DC67025 |
Mipomersen
Featured
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH). The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Mipomersen sodium) that retains the same biological activity. |
1000120-98-8 |
DC67026 | Olpasiran Featured | |
DC67027 | Onpattro Featured | |
DC67028 | Pegaptanib Featured | |
DC67029 |
KT-413
Featured
KT-413 (example I-3) is a potent IRAK degrader. |
2655656-99-6 |
DC67030 |
Ongericimab
Featured
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia. |
2145096-91-7 |
DC67031 |
Tafolecimab
Featured
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia. |
2225109-03-3 |
DC67032 |
Frovocimab
Featured
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9. |
1643672-70-1 |
DC67033 |
Bococizumab
Featured
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia. |
1407495-02-6 |
DC67034 |
Ebronucimab
Featured
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells. |
2304800-90-4 |
DC67035 | Boehringer anti-PCSK9 Featured | |
DC67036 | Merck patent anti-PCSK9 Featured | |
DC67037 | Schering patent anti-PCSK9 Featured | |
DC67038 |
Dostarlimab
Featured
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively. |
2022215-59-2 |
DC67039 |
Camrelizumab
Featured
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al. |
1798286-48-2 |
DC67040 |
Finotonlimab(SCT-I10A)
Featured
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research. |
|
DC67041 |
Geptanolimab
Featured
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer. |
2348469-43-0 |
DC67042 |
Iparomlimab
Featured
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research. |
2417649-33-1 |